多西紫杉醇-话题@MedSci

#多西紫杉醇#

14篇内容 | 752人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2181792, encodeId=0e1f2181e92ca, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=2a4d391818a' target=_blank style='color:#2F92EE;'>#吡咯替尼#</a> <a href='/topic/show?id=1bdc43456b3' target=_blank style='color:#2F92EE;'>#多西紫杉醇#</a>, objectTitle=Nat. Commun | 吡罗替尼联合多西紫杉醇作为HER2阳性转移性乳腺癌的一线治疗：PANDORA II期试验, objectType=article, longId=808861, objectId=f441808861fc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240110/1704893487429_6145188.png, objectUrl=/article/show_article.do?id=f441808861fc, replyNumber=0, likeNumber=26, createdTime=2024-01-15, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f441808861fc, moduleTitle=Nat. Commun | 吡罗替尼联合多西紫杉醇作为HER2阳性转移性乳腺癌的一线治疗：PANDORA II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f441808861fc)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1587290, encodeId=2275158e290b3, content=<a href='/topic/show?id=1bdc43456b3' target=_blank style='color:#2F92EE;'>#多西紫杉醇#</a>, objectTitle=ASCO2019 |帕妥珠单抗、曲妥珠单抗和多西紫杉醇联合一线治疗her2阳性转移性乳腺癌的中国桥接研究（PUFFIN）, objectType=article, longId=167604, objectId=9de016e60451, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9de016e60451, replyNumber=0, likeNumber=32, createdTime=2019-06-05, rootId=0, userName=zhaozhouchifen, userId=2f2717457850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9de016e60451, moduleTitle=ASCO2019 |帕妥珠单抗、曲妥珠单抗和多西紫杉醇联合一线治疗her2阳性转移性乳腺癌的中国桥接研究（PUFFIN）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9de016e60451)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587289, encodeId=4ec7158e2897b, content=<a href='/topic/show?id=1bdc43456b3' target=_blank style='color:#2F92EE;'>#多西紫杉醇#</a>, objectTitle=Lancet：多西紫杉醇3D疗法（FLOT）治疗晚期可切除胃癌, objectType=article, longId=164240, objectId=143d164240fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=143d164240fb, replyNumber=0, likeNumber=31, createdTime=2019-04-15, rootId=0, userName=zhaozhouchifen, userId=2f2717457850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=143d164240fb, moduleTitle=Lancet：多西紫杉醇3D疗法（FLOT）治疗晚期可切除胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=143d164240fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587288, encodeId=d567158e288a7, content=<a href='/topic/show?id=1bdc43456b3' target=_blank style='color:#2F92EE;'>#多西紫杉醇#</a>, objectTitle=CLIN CANCER RES：三阴性乳腺癌患者新辅助卡铂联合多西紫杉醇治疗后病情缓解情况及预后, objectType=article, longId=155771, objectId=2def155e7198, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2def155e7198, replyNumber=0, likeNumber=30, createdTime=2018-12-15, rootId=0, userName=zhaozhouchifen, userId=2f2717457850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2def155e7198, moduleTitle=CLIN CANCER RES：三阴性乳腺癌患者新辅助卡铂联合多西紫杉醇治疗后病情缓解情况及预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2def155e7198)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587287, encodeId=afc4158e287a2, content=<a href='/topic/show?id=1bdc43456b3' target=_blank style='color:#2F92EE;'>#多西紫杉醇#</a>, objectTitle=JCO：曲妥珠单抗联合多西紫杉醇治疗晚期涎腺导管癌, objectType=article, longId=154708, objectId=3432154e08da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3432154e08da, replyNumber=0, likeNumber=31, createdTime=2018-12-01, rootId=0, userName=zhaozhouchifen, userId=2f2717457850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3432154e08da, moduleTitle=JCO：曲妥珠单抗联合多西紫杉醇治疗晚期涎腺导管癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3432154e08da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587286, encodeId=c3b2158e28633, content=<a href='/topic/show?id=1bdc43456b3' target=_blank style='color:#2F92EE;'>#多西紫杉醇#</a>, objectTitle=JCO：吉西他滨联合多西紫杉醇序贯阿霉素治疗子宫平滑肌肉瘤, objectType=article, longId=152444, objectId=6f4115244469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f4115244469, replyNumber=0, likeNumber=38, createdTime=2018-11-02, rootId=0, userName=zhaozhouchifen, userId=2f2717457850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f4115244469, moduleTitle=JCO：吉西他滨联合多西紫杉醇序贯阿霉素治疗子宫平滑肌肉瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f4115244469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587285, encodeId=e3c0158e285f9, content=<a href='/topic/show?id=1bdc43456b3' target=_blank style='color:#2F92EE;'>#多西紫杉醇#</a>, objectTitle=Lancet Oncol：多西紫杉醇、顺铂和氟尿嘧啶联合化疗用于晚期肛门鳞状细胞癌, objectType=article, longId=142337, objectId=41ec14233e9b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41ec14233e9b, replyNumber=0, likeNumber=31, createdTime=2018-07-05, rootId=0, userName=zhaozhouchifen, userId=2f2717457850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41ec14233e9b, moduleTitle=Lancet Oncol：多西紫杉醇、顺铂和氟尿嘧啶联合化疗用于晚期肛门鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41ec14233e9b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587284, encodeId=78ea158e28404, content=<a href='/topic/show?id=1bdc43456b3' target=_blank style='color:#2F92EE;'>#多西紫杉醇#</a>, objectTitle=EUR J Cancer：来源于ModraDoc001或ModraDoc006的多西紫杉醇联合利托那韦的剂量扩大研究, objectType=article, longId=124483, objectId=4a021244830a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a021244830a, replyNumber=0, likeNumber=26, createdTime=2017-12-26, rootId=0, userName=zhaozhouchifen, userId=2f2717457850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a021244830a, moduleTitle=EUR J Cancer：来源于ModraDoc001或ModraDoc006的多西紫杉醇联合利托那韦的剂量扩大研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a021244830a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587283, encodeId=95d8158e28337, content=<a href='/topic/show?id=1bdc43456b3' target=_blank style='color:#2F92EE;'>#多西紫杉醇#</a>, objectTitle=EUR J CANCER：多西紫杉醇 vs多西紫杉醇联合卡铂治疗去势难治性前列腺癌的随机II期临床试验：RECARDO试验, objectType=article, longId=124106, objectId=bed9124106d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bed9124106d6, replyNumber=0, likeNumber=26, createdTime=2017-12-22, rootId=0, userName=zhaozhouchifen, userId=2f2717457850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bed9124106d6, moduleTitle=EUR J CANCER：多西紫杉醇 vs多西紫杉醇联合卡铂治疗去势难治性前列腺癌的随机II期临床试验：RECARDO试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bed9124106d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587282, encodeId=fea8158e2821e, content=<a href='/topic/show?id=1bdc43456b3' target=_blank style='color:#2F92EE;'>#多西紫杉醇#</a>, objectTitle=Eur Urol：之前接受雄激素剥夺疗法（加或不加用多西紫杉醇）的转移未去势前列腺癌患者，进展后再治疗的抗癌活性和耐受性研究。, objectType=article, longId=118241, objectId=3b72118241ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b72118241ce, replyNumber=0, likeNumber=32, createdTime=2017-11-02, rootId=0, userName=zhaozhouchifen, userId=2f2717457850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b72118241ce, moduleTitle=Eur Urol：之前接受雄激素剥夺疗法（加或不加用多西紫杉醇）的转移未去势前列腺癌患者，进展后再治疗的抗癌活性和耐受性研究。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b72118241ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587281, encodeId=1bb3158e28191, content=<a href='/topic/show?id=1bdc43456b3' target=_blank style='color:#2F92EE;'>#多西紫杉醇#</a>, objectTitle=Sci Rep：上海中医药大学研究人员设计新型纳米载体提高多西紫杉醇的口服抗肿瘤效果, objectType=article, longId=97886, objectId=225a9e88655, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=225a9e88655, replyNumber=0, likeNumber=49, createdTime=2017-05-06, rootId=0, userName=zhaozhouchifen, userId=2f2717457850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=225a9e88655, moduleTitle=Sci Rep：上海中医药大学研究人员设计新型纳米载体提高多西紫杉醇的口服抗肿瘤效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=225a9e88655)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587280, encodeId=3910158e28084, content=<a href='/topic/show?id=1bdc43456b3' target=_blank style='color:#2F92EE;'>#多西紫杉醇#</a>, objectTitle=NEJM：纳武单抗 vs 多西紫杉醇治疗晚期非鳞状非小细胞肺癌, objectType=article, longId=57641, objectId=38235e641a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38235e641a2, replyNumber=0, likeNumber=40, createdTime=2015-10-24, rootId=0, userName=zhaozhouchifen, userId=2f2717457850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38235e641a2, moduleTitle=NEJM：纳武单抗 vs 多西紫杉醇治疗晚期非鳞状非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38235e641a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587279, encodeId=1766158e2793e, content=<a href='/topic/show?id=1bdc43456b3' target=_blank style='color:#2F92EE;'>#多西紫杉醇#</a>, objectTitle=ASCO 2014：低剂量环磷酰胺+多西紫杉醇一线治疗非三阴性乳腺癌的疗效, objectType=article, longId=35643, objectId=dedf356438d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dedf356438d, replyNumber=0, likeNumber=28, createdTime=2014-06-02, rootId=0, userName=zhaozhouchifen, userId=2f2717457850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dedf356438d, moduleTitle=ASCO 2014：低剂量环磷酰胺+多西紫杉醇一线治疗非三阴性乳腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dedf356438d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587278, encodeId=c7fc158e27881, content=<a href='/topic/show?id=1bdc43456b3' target=_blank style='color:#2F92EE;'>#多西紫杉醇#</a>, objectTitle=Lancet Oncology:Selumetinib+多西紫杉醇治疗NSCLC或更有效, objectType=article, longId=12113, objectId=08f9121136d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08f9121136d, replyNumber=0, likeNumber=37, createdTime=2012-12-05, rootId=0, userName=zhaozhouchifen, userId=2f2717457850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08f9121136d, moduleTitle=Lancet Oncology:Selumetinib+多西紫杉醇治疗NSCLC或更有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08f9121136d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1587277, encodeId=de75158e27778, content=<a href='/topic/show?id=1bdc43456b3' target=_blank style='color:#2F92EE;'>#多西紫杉醇#</a>, objectTitle=JNCI:胃癌患者BRCA1 高表达可从多西紫杉醇化疗方案获益, objectType=article, longId=3886, objectId=b265388684, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b265388684, replyNumber=0, likeNumber=29, createdTime=2012-02-08, rootId=0, userName=zhaozhouchifen, userId=2f2717457850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b265388684, moduleTitle=JNCI:胃癌患者BRCA1 高表达可从多西紫杉醇化疗方案获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b265388684)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

多西紫杉醇

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#乳腺癌# #吡咯替尼# #多西紫杉醇#

Nat. Commun | 吡罗替尼联合多西紫杉醇作为HER2阳性转移性乳腺癌的一线治疗：PANDORA II期试验

2024-01-15发表于上海

zhaozhouchifen (审核中...)

前往app查看评论内容

#多西紫杉醇#

ASCO2019 |帕妥珠单抗、曲妥珠单抗和多西紫杉醇联合一线治疗her2阳性转移性乳腺癌的中国桥接研究（PUFFIN）

2019-06-05

zhaozhouchifen (审核中...)

前往app查看评论内容

#多西紫杉醇#

Lancet：多西紫杉醇3D疗法（FLOT）治疗晚期可切除胃癌

2019-04-15

zhaozhouchifen (审核中...)

前往app查看评论内容

#多西紫杉醇#

CLIN CANCER RES：三阴性乳腺癌患者新辅助卡铂联合多西紫杉醇治疗后病情缓解情况及预后

2018-12-15

zhaozhouchifen (审核中...)

前往app查看评论内容

#多西紫杉醇#

JCO：曲妥珠单抗联合多西紫杉醇治疗晚期涎腺导管癌

2018-12-01

zhaozhouchifen (审核中...)

前往app查看评论内容

#多西紫杉醇#

JCO：吉西他滨联合多西紫杉醇序贯阿霉素治疗子宫平滑肌肉瘤

2018-11-02

zhaozhouchifen (审核中...)

前往app查看评论内容

#多西紫杉醇#

Lancet Oncol：多西紫杉醇、顺铂和氟尿嘧啶联合化疗用于晚期肛门鳞状细胞癌

2018-07-05

zhaozhouchifen (审核中...)

前往app查看评论内容

#多西紫杉醇#

EUR J Cancer：来源于ModraDoc001或ModraDoc006的多西紫杉醇联合利托那韦的剂量扩大研究

2017-12-26

zhaozhouchifen (审核中...)

前往app查看评论内容

#多西紫杉醇#

EUR J CANCER：多西紫杉醇 vs多西紫杉醇联合卡铂治疗去势难治性前列腺癌的随机II期临床试验：RECARDO试验

2017-12-22

zhaozhouchifen (审核中...)

前往app查看评论内容

#多西紫杉醇#

Eur Urol：之前接受雄激素剥夺疗法（加或不加用多西紫杉醇）的转移未去势前列腺癌患者，进展后再治疗的抗癌活性和耐受性研究。

2017-11-02

zhaozhouchifen (审核中...)

前往app查看评论内容

#多西紫杉醇#

Sci Rep：上海中医药大学研究人员设计新型纳米载体提高多西紫杉醇的口服抗肿瘤效果

2017-05-06

zhaozhouchifen (审核中...)

前往app查看评论内容

#多西紫杉醇#

NEJM：纳武单抗 vs 多西紫杉醇治疗晚期非鳞状非小细胞肺癌

2015-10-24

zhaozhouchifen (审核中...)

前往app查看评论内容

#多西紫杉醇#

ASCO 2014：低剂量环磷酰胺+多西紫杉醇一线治疗非三阴性乳腺癌的疗效

2014-06-02

zhaozhouchifen (审核中...)

前往app查看评论内容

#多西紫杉醇#

Lancet Oncology:Selumetinib+多西紫杉醇治疗NSCLC或更有效

2012-12-05

zhaozhouchifen (审核中...)

前往app查看评论内容

#多西紫杉醇#

JNCI:胃癌患者BRCA1 高表达可从多西紫杉醇化疗方案获益

2012-02-08

科室
- - 订阅+
  - 更多科室
工具
服务